title: Atrial fibrillation following subconjunctival injection of mydricaine number 02.
abstract: Mydricaine is a mydriatic agent used as a subconjunctival injection to maintain perioperative mydriasis. The drug consists of a mixture of 1.3 mg atropine sulphate, 0.12 mg adrenaline and 8.4 mg procaine hydrochloride in a single vial of 0.4 mL. It is common practice to use mydricaine injections during vitreoretinal surgery in the Royal Adelaide Hospital. Even though the drug is used widely in many vitreoretinal centres, mydricaine is not listed in the British National Formulary nor Monthly Index of Medical Specialities. Therefore, case reports provide the main forum for reporting side-effects.
authors.forename: Ranasiri D
authors.initials: RD
authors.lastname: Keembiyage
authors.forename: Grant L
authors.initials: GL
authors.lastname: Raymond
authors.forename: Henry S
authors.initials: HS
authors.lastname: Newland
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000139:chemically induced*; D001285:Atropine / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects; D003228:Conjunctiva; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D004837:Epinephrine / Q000009:adverse effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007267:Injections; D007906:Lens Subluxation / Q000601:surgery; D009184:Mydriatics / Q000009:adverse effects*; D011343:Procaine / Q000009:adverse effects; D014821:Vitrectomy
chemical_list: D009184:Mydriatics; D011343:Procaine; D001285:Atropine; D004837:Epinephrine